CardioExchange Archive

August 12th, 2014

What Can We Really Deduce from ACCORD?

Kasia Lipska, MD, MHS

For Kasia Lipska, post hoc analyses of intensive glucose lowering in the ACCORD trial require greater scrutiny.

---

August 11th, 2014

Selections from Richard Lehman’s Literature Review: August 11th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include the effects of intensive glucose control on ischemic heart disease and a meta-analysis of the effects of thrombolysis with alteplase for acute ischemic stroke.

---

March 10th, 2014

Selections from Richard Lehman’s Literature Review: March 10th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include cognitive function and brain structure in type 2 diabetics after intensive lowering of BP and lipid levels, the association of β-blocker therapy with risks of adverse CV events and deaths in those with ischemic heart disease undergoing noncardiac surgery, and more.

---

April 2nd, 2013

Intensive Glucose Control and ESRD – Strongest Evidence?

Kasia Lipska, MD, MHS

Kasia Lipska unpacks a report in Kidney International that claims to provide “the strongest evidence yet” of a protective effect of intensive glucose lowering against end-stage renal disease in type 2 diabetes.

---

October 8th, 2010

Analysis of ADVANCE Explores Role of Hypoglycemia

Larry Husten, PHD

A new analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation) trial sheds light on the role of hypoglycemia in recent trials of glucose control. In a paper in the New England Journal of Medicine, the ADVANCE investigators report that 2.1% of 11,140 patients with type 2 diabetes […]

---